Abstract | OBJECTIVE: METHODS: Seventeen patients were enrolled and 15 completed a prospective open-label 6-week study of amoxapine starting with a fixed-starting dose (150 mg/h) with standardized titration up to 250 mg/h, if required. Positive, negative, affective symptoms and side-effects were monitored using standardized weekly assessments. RESULTS:
Amoxapine (median final dose 210 mg/h) was well-tolerated and showed significant improvement in positive and negative symptoms (both p<0.001), with a trend towards improvement in mood symptoms and no treatment-emergent extrapyramidal side-effects, akathisia or weight gain. Prolactin elevation was observed. CONCLUSION: These clinical data lend support to the pre-clinical suggestions that amoxapine may be an atypical antipsychotic. Given its lack of weight gain and that it is considerably less expensive than current options, amoxapine could be a valuable alternative for some patients. These considerations strongly call for more systematic, double-blind studies of amoxapine as an atypical antipsychotic.
|
Authors | Rogelio Apiquian, Elena Ulloa, Ana Fresan, Cristina Loyzaga, Humberto Nicolini, Shitij Kapur |
Journal | Schizophrenia research
(Schizophr Res)
Vol. 59
Issue 1
Pg. 35-9
(Jan 01 2003)
ISSN: 0920-9964 [Print] Netherlands |
PMID | 12413640
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Neurotransmitter Uptake Inhibitors
- Amoxapine
|
Topics |
- Adolescent
- Adult
- Amoxapine
(adverse effects, pharmacology, therapeutic use)
- Analysis of Variance
- Antipsychotic Agents
(adverse effects, pharmacology, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Neurotransmitter Uptake Inhibitors
(adverse effects, pharmacology, therapeutic use)
- Prospective Studies
- Schizophrenia
(drug therapy)
|